Manganese oxide

Genetic toxicity: in vivo

Administrative data

Endpoint:

in vivo mammalian somatic cell study: cytogenicity / erythrocyte micronucleus

Remarks:

Type of genotoxicity: chromosome aberration

Type of information:

experimental study

Adequacy of study:

key study

Study period:

2009-04-15 to 2009-09-04

Reliability:

1 (reliable without restriction)

Rationale for reliability incl. deficiencies:

other: GLP study conducted to current accepted guidelines.

Data source

Reference

Reference Type:

study report

Title:

Unnamed

Year:

2009

Report date:

2009

Materials and methods

Test guideline

Qualifier:

according to guideline

Guideline:

OECD Guideline 474 (Mammalian Erythrocyte Micronucleus Test)

Deviations:

no

GLP compliance:

yes (incl. QA statement)

Type of assay:

micronucleus assay

Test material

Test material information

Constituent 1

Reference substance name:

manganese chloride tetrahydrate

IUPAC Name:

manganese chloride tetrahydrate

Constituent 2

Reference substance name:

13446-34-9

Cas Number:

13446-34-9

IUPAC Name:

13446-34-9

Constituent 3

Reference substance name:

Manganese dichloride

EC Number:

231-869-6

EC Name:

Manganese dichloride

Cas Number:

7773-01-5

Molecular formula:

Cl2Mn

IUPAC Name:

manganese(2+) dichloride

Details on test material:

- Name of test material : manganese chloride tetrahydrate
- Molecular formula : MnCl2
- Physical state: Liquid
- Storage condition of test material: Bulk test item was stored in its shipping container at ambient temperature (approximately 15-30 °C), as per the instructions accompanying the test item. A 1 gram reserve sample of the neat test item was stored at ambient temperature (approximately 15-30 °C)

Test animals

Species:

mouse

Strain:

B6C3F1

Sex:

female

Details on test animals or test system and environmental conditions:

TEST ANIMALS
- Source: Charles River Laboratories, Raleigh, NC USA
- Age at study initiation: Approximately 8 weeks
- Weight at study initiation: 18.9-22.2 g
- Assigned to test groups randomly: yes under following basis: Animals were stratified by body weight and assigned to a dose group such that mean animal weights across dose groups were approximately equal.
- Housing: Animals were housed individually housed in polycarbonate cages with absorbent hardwood bedding (Betachip, Northeastern products Corp., Warrensbury, NY USA). Animals were transferred to clean cages weekly.
- Diet : Purina Certified Rodent Chow 5002 (Ralston Purina, St. Louis, MO, USA) available ad libitum.
- Water : Reverse-osmosis water was provided ad libitum using plastic water bottles with stainless steel sipper tubes. Fresh water was supplied weekly.
- Acclimation period: All animals were examined by a veterinarian or other appropriate persons during the acclimation period to assess the health status. All animals were re-examined at the end of the acclimation period.


ENVIRONMENTAL CONDITIONS
- Temperature (°C): 18-26 °C
- Humidity (%): 30-70 %
- Photoperiod (hrs dark / hrs light): 12 hour light/12 hour dark

Administration / exposure

Route of administration:

oral: gavage

Vehicle:

- Vehicle used: physiol. saline
- Amount of vehicle : 10 mL/kg BW

Details on exposure:

PREPARATION OF DOSING SOLUTIONS:
The dosing solutions were made from manganese chloride tetrahydrate and concentrations calculated as manganese (Mn2+). The manganese chloride dosing solutions were freshly prepared in 0.9 % saline on each day of treatment.

DOSE ADMINISTRATION
The animals were dosed on days 1 and 2 via oral gavage in a single dose using a stainless steel or disposable gavage needle. Each dose was administered 24 ± 0.5 hours after the first dose.

JUSTIFICATION OF DOSING ROUTE
An appropriate route of human exposure is oral.

Duration of treatment / exposure:

Single oral exposures

Frequency of treatment:

Animals were dosed twice within 24 hours.

Post exposure period:

46 hours

Doses / concentrations

Doses / concentrations 1

Remarks:

Doses / Concentrations:
25 mg/kg
Basis:
nominal conc.

Doses / concentrations 2

Remarks:

Doses / Concentrations:
50 mg/kg
Basis:
nominal conc.

Doses / concentrations 3

Remarks:

Doses / Concentrations:
100 mg/kg
Basis:
nominal conc.

Doses / concentrations 4

Remarks:

Doses / Concentrations:
200 mg/kg
Basis:
nominal conc.

No. of animals per sex per dose:

5 animals were included in each dosing group

Control animals:

yes, concurrent vehicle

Positive control(s):

- Positive control : cyclophosphamide
- Route of administration: oral gavage
- Doses / concentrations: 25 mg/kg/day in 0.9 % saline

Examinations

Tissues and cell types examined:

Blood was collected from each mouse for analysis. 350 µL of MicroFlowPLUS kit Solution B (anticoagulant) was aliquoted into an appropriately labelled sterile microcentrifuge tube for each animal. One day prior to collection of blood, 2 mL of MicroFlowPLUS Solution A (fixative) was aliquoted into two appropriately labelled 15 mL polypropylene conical tubes for each study animal. Immediately prior to use, each tube containing Solution B was shaken immediately before bleeding each animals to coat the inside of the tube. Following anaesthesia by isofluorane, blood was collected from the retro-orbital sinus by heparinized hemocrit. 120 (± 20) µL of blood was dispensed into the corresponding microcentrifuge tube containing Solution B and mixed by inverting several times. The stabilised blood samples were maintained at room temperature and fixed within 5 hours of collection.

Details of tissue and slide preparation:

CRITERIA FOR DOSE SELECTION:
Results from a renge finding study.


METHOD OF ANALYSIS: Blood samples were fixed by 180 µL of each blood-Solution B sample was withdrawn from the tube. All tubes of fixed cells were quickly transferred back to the freezer and stored at -75 ± 10 °C for at least 24 hours prior to processing for flow cytometry analysis of reticulocytes. Flow cytometry of MN was performed using MicroFlowPLUS (Mouse) kit reagents (Litron Laboratories, Rochester NY) according to the kit’s instructional manual with minimal modification, 1) 1 mL of fixed cells for each experimental sample was transferred to a tube containing 12 mL of Solution C and washed in preparation for labelling and 2) volumes of labelling solution I, labelling solution II and DNA stain were adjusted as appropriate each day to minimise the use of excess reagents. The MicroFlowPLUS method utilises CD71 and CD61 antibodies as well as a fixed malaria biostandard that contains DNA in the same size range as MN to properly configure the flow cytometer to exclude platelets (CD61+) and only count micronucleus events in erythrocytes. For each peripheral blood sample, 20,000 immature (CD71+) reticulocytes were analysed to determine the frequency of both MN-RET and micronucleated mature (CD41-) normochromatic erythrocytes (NCE). A BD FACSCalibur™, a four-colour, dual laser benchtop system, was used for MN-RET and MN-NCE analysis.

Evaluation criteria:

Positive control:
The reference control (positive control) cyclophosphamide, is expected to induce an increase in the frequency of MN-RET at p < 0.05.
Test item:
For negative studies, the highest test item concentration evaluated for MN induction must, unless precleded by the use of the limit dose of 2000 mg/kg, induce bone marrow or animal toxicity or be a dose only slightly lower than that which would be expected to induce mortality.

Criteria for a positive response:
A decision by an experienced scientific investigator to classify a test item as negative, equivocal, or positive for genotoxicity in this assay is based on the biological relevance of the equivocal, or positive for genotoxicity based on the biological relevance of the results, taking into consideration the appropriateness of the concurrent control data, the results of the statistical analysis of the experimental data and the extent of cytotoxicity.

Statistics:

Statistical analysis was conducted on the frequency of MN-RET, MN-NCE and RET. Using individual animal data, the analysis involveed the use of the Shapiro-Wilk test with a confidence level of 95 % to determine the normality of the MN-RET data in the vehicle control group.

Normally distributed MN-RET frequency data were then analysed for linearity and variance between treatment groups using linear regression and one-way ANOVA analyses, respectively. The Dunnett multiple comparison test was used to determine if a treatment groups was significantly different (p < 0.05) from vehicle controls. A one-tailed independent t-test was used to verify a positive response to the control compound, cyclophosphamide.

Results and discussion

Test results

Sex:

female

Genotoxicity:

negative

Toxicity:

no effects

Remarks:

Animal number 23 which showed hunched posture at the 1 hour post dose observation on Day 1 of the study. All other animals were found to be normal throughout the study

Vehicle controls validity:

valid

Negative controls validity:

not examined

Positive controls validity:

valid

Additional information on results:

RESULTS OF RANGE-FINDING STUDY
- Dose range: 125-1000 mg/kg bw
- Clinical signs of toxicity in test animals: Please refer to Range finding study under section: Remarks on results including tables and figures for full details.

RESULTS OF DEFINITIVE STUDY
- Micronucleus Assay Results (incl. statistical analysis): The percent of micronucleated cells among 20,000 RET and ≥900,000 NCE from the peripheral blood of B6C3F1 mice treated with the vehicle, reference chemical, and test item as analysed by flow cytometry. Based on a one-way ANOVA (p = 0.415) test and Dunnett pair wise comparison of each dose group against the concurrent control, the group %MN-RET means comparison of each dose group against the concurrent control, the group %MN-RET means were not significantly increased by treatment with manganese at dose levels 25, 50, 100 or 200 mg/kg BW. No dose response was indicated by linear regression analysis (p = 0.509). There was also no impact on treatment with manganese on %MN-NCE (p = 0.3939) or %RET (p = 0.7375). Treatment with 25 mg/kg/day of the reference control, cyclophosphamide, induced a statistically significant increase in MN-RET (p < 0.0001) as well as MN-NCE (p = 0.0012) and resulted in a 40.6% decrease in %RET.
- Clinical signs of toxicity in test animals: Cage side observations were conducted prior to dosing and at 1 and 4 hours post-dose each day. All animals in the definitive study were considered normal throughout with the exception of animal number 23 which showed hunched posture at the 1 hour post dose observation on Day 1 of the study.

Any other information on results incl. tables

Range finding study:

Male and female mice were treated with Mn^{2 +}at 1000, 500, 250 and 125 mg/kg BW. A few minutes after dosing, the fist animal (male) in the 1000 mg/kg treatment group exhibited seizures and convulsions. This animal was euthanised and no further mice were treated in this dose group. At 1 -hour post-treatment observation period, male and female mice in the 500 mg/kg treatment groups exhibited lethargy, uncoordinated movement, and abnormal breathing. These mice were euthanised after the 1 -hour observation period. Also at the 1 -hour post-treatment observation period, the mice in the 250 mg/kg treatment group exhibited hunched posture, decreased movement and piloerection. At the 4 -hour post-treatment observation, the mice in the 250 mg/kg group continued to exhibit a hunched posture, decreased movement and lethargy, with one animal found dead. These mice were immediately euthanised. The control mice and the mice in the 125 mg/kg treatment group were normal throughout both days of treatment.

Based on the results of the first day of treatment, the study was discontinued and restarted using 175, 200 and 225 mg/kg BW. At the 1 -hour post-treatment observation, the female mice in the 225 mg/kg group exhibited a hunched posture, decreased movement and piloerection. These mice were immediately euthanised. All other animals were considered normal throughout the study.

Based on the range-finding study, the selected doses for the definitive study were 25, 50, 100 and 200 mg/kg manganese. Female mice were dosed chosen for the definitive test.

Definitive test:

Table 2: Frequency of RET, MN-RET and MN-NCE in peripheral blood reticulocytes of female B6C3F1 mice administered manganese and cyclophosphamide by oral gavage

 

Dose (mg/kg)	% MN-RET	SEM	% MN-NCE	SEM	% RET	SEM
Vehicle
0	0.202	0.006	0.118	0.001	1.725	0.172
Manganese
25 50 100 200	0.173 0.202 0.197 0.180	0.012 0.017 0.019 0.008	0.120 0.113 0.122 0.112	0.007 0.005 0.003 0.004	1.527 1.565 1.697 1.675	0.087 0.191 0.067 0.105
Cyclophosphamide
25	1.057	0.020	0.144	0.004	1.025	0.077

Applicant's summary and conclusion

Conclusions:

Interpretation of results: Negative
Manganese administered twice at 24 ± 0.5 hour intervals to female B6C3F1 mice by oral gavage at 25, 50, 100 or 200 mg/kg BW did not induce chromosomal damage.

Executive summary:

This was chosen as Key study as it is the only available study which is of relevance and of sufficient quality for classification and labelling and for risk assessment.

 

The reference control, cyclophosphamide, administered at 25 mg/kg/day under the same dosing regimen, induced a significant increase in the frequency of MN-RET (p<0.0001) and MN-NCE (p = 0.0012) and a decrease in % RET. Also the quality criteria of the study have been fulfilled as the study was conducted to OCED 474 (Mammalian Erythrocyte) guidelines and to GLP.

  

Lack of any observed effects in % MN-RET, %MN-NCE and % RET in the study supports the lack of classification and labelling of this substance.